<code id='5F524C55B1'></code><style id='5F524C55B1'></style>
    • <acronym id='5F524C55B1'></acronym>
      <center id='5F524C55B1'><center id='5F524C55B1'><tfoot id='5F524C55B1'></tfoot></center><abbr id='5F524C55B1'><dir id='5F524C55B1'><tfoot id='5F524C55B1'></tfoot><noframes id='5F524C55B1'>

    • <optgroup id='5F524C55B1'><strike id='5F524C55B1'><sup id='5F524C55B1'></sup></strike><code id='5F524C55B1'></code></optgroup>
        1. <b id='5F524C55B1'><label id='5F524C55B1'><select id='5F524C55B1'><dt id='5F524C55B1'><span id='5F524C55B1'></span></dt></select></label></b><u id='5F524C55B1'></u>
          <i id='5F524C55B1'><strike id='5F524C55B1'><tt id='5F524C55B1'><pre id='5F524C55B1'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:6
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

          The next ALS data readout — overdue but important

          A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

          advertisement

          In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          'Screen and refer' systems are hurting patients
          'Screen and refer' systems are hurting patients

          AdobeIoncesawapatientwhocametotheemergencyroomwithinjuriesthatwereclearlyrelatedtodomesticviolence.I

          read more
          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more

          EPA limits use of carcinogenic gas for sterilizing medical devices

          TheagencyfirstproposedlimitsonthegasinApril2023,withthegoalofreducingemissionsby80%.Now,theagencyisp